Pain and emotional well-being outcomes in southwest oncology group-directed intergroup trial S0205: A phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages 3611-3616

  Moinpour, Carol M ^a   Vaught, Nancy L ^a   Goldman, Bryan ^a   Redman, Mary W ^a   Philip, Philip A ^a   Millwood, Barbara ^a   Lippman, Scott M ^a   Seay, Thomas E ^a   Flynn, Patrick J ^a   O'Reilly, Eileen M ^a   Rowland, Kendrith M ^a   Wong, Ralph P ^a   Benedetti, Jacqueline ^a   Blanke, Charles D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CETUXIMAB; GEMCITABINE; OPIATE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRIEF PAIN INVENTORY; CANCER PALLIATIVE THERAPY; EMOTION; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAIN; PAIN ASSESSMENT; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME; WELLBEING; ADENOCARCINOMA; ATTITUDE TO HEALTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MENTAL HEALTH; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PSYCHOLOGICAL ASPECT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATTITUDE TO HEALTH; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; PAIN; PANCREATIC NEOPLASMS; QUALITY OF LIFE;

EID: 77955866900     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.8285     Document Type: Article

References (40)

1. Jacobson JS: Quality and quantity of life with pancreatic cancer. Digestion 74:116-117, 2006
2. Greenwald HP, Bonica JJ, Bergner M: The prevalence of pain in four cancers. Cancer 60:2563-2569, 1987 (Pubitemid 17157271)
3. Fasanella KE, Davis B, Lyons J, et al: Pain in chronic pancreatitis and pancreatic cancer. Gastroenterol Clin North Am 36:335-364, ix, 2007
4. Kelsen DP, Portenoy RK, Thaler HT, et al: Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 13:748-755, 1995
5. Schmier J, Elixhauser A, Halpern MT: Healthrelated quality of life evaluations of gastric and pancreatic cancer. Hepatogastroenterology 46:1998-2004, 1999
6. Zabora J, BrintzenhofeSzoc K, Curbow B, et al: The prevalence of psychological distress by cancer site. Psychooncology 10:19-28, 2001 (Pubitemid 32106774)
7. Labori KJ, Hjermstad MJ, Wester T, et al: Symptom profiles and palliative care in advanced pancreatic cancer: A prospective study. Support Care Cancer 14:1126-1133, 2006 (Pubitemid 44898795)
8. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup trial S0205. J Clin Oncol 28:3605-3610, 2010
9. Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer 50:1913-1918, 1982
10. Daut RL, Cleeland CS, Flannery R: Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17:197-210, 1983 (Pubitemid 13012221)
11. Cleeland C: Pain assessment in cancer, in Osoba D (ed), Effects of Cancer on Quality of Life. Boca Raton, FL, CRC Press, 1991, pp 293-305
12. Cleeland CS: The Brief Pain Inventory, a measure of cancer pain and its impact. International Society for Quality of Life Research Newsletter 9:5-6, 1994
13. Serlin RC, Mendoza TR, Nakamura Y, et al: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277-284, 1995
14. Cleeland CS, Gonin R, Hatfield AK, et al: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592-596, 1994 (Pubitemid 24065792)
15. Farrar JT, Young JP Jr, LaMoreaux L, et al: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149-158, 2001 (Pubitemid 33016608)
16. Heffernan N, Cella D, Webster K, et al: Measuring health-related quality of life in patients with hepatobiliary cancers: The functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol 20:2229-2239, 2002 (Pubitemid 34441650)
17. Bretscher M, Rummans T, Sloan J, et al: Quality of life in hospice patients: A pilot study. Psychosomatics 40:309-313, 1999 (Pubitemid 29315951)
18. Decker PA, Ballman KV, Locke DE, et al: Validation of single item linear analogue scale assessments (LASAs) for assessing quality of life (QOL) in patients with newly diagnosed high-grade gliomas. J Clin Oncol 24:488s, 2006 (abstr 8583)
19. Locke DEC, Decker PA, Sloan JA, et al: Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. Journal of Pain and Symptom Management 34:628-638, 2007 (Pubitemid 350161248)
20. Hyland ME, Sodergren SC: Development of a new type of global quality of life scale, and comparison of performance and preference for 12 global scales. Qual Life Res 5:469-480, 1996 (Pubitemid 26382281)
21. Grunberg SM, Groshen S, Steingass S, et al: Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res 5:65-72, 1996 (Pubitemid 26100504)
22. Wilkie D, Lovejoy N, Dodd M, et al: Cancer pain intensity measurement: Concurrent validity of three tools - finger dynamometer, pain intensity number scale, visual analogue scale. The Hospice Journal 6:1-13, 1990 (Pubitemid 20293260)
23. Nunnally JC: Psychometric theory. New York, NY, McGraw-Hill, 1978
24. Sloan JA, Loprinzi CL, Kuross SA, et al: Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 16:3662-3673, 1998 (Pubitemid 28506782)
25. Geyer CE Jr, Green SJ, Moinpour CM, et al: Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study. Breast Cancer Res Treat 51:169-181, 1998 (Pubitemid 28561421)
26. Berry DL, Moinpour CM, Jiang CS, et al: Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24:2828-2835, 2006 (Pubitemid 46630582)
27. Hopwood P, Stephens R, Machin D, et al: Approaches to the analysis of quality of life data: Experiences gained form a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual Life Res 3:339-352, 1994 (Pubitemid 24358750)
28. Moinpour CM, Sawyers TJ, McKnight B, et al: Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology 9:340-354, 2000
29. Fairclough DL: Design and Analysis of Quality of Life Studies in Clinical Trials: Interdisciplinary Statistics. Boca Raton, FL, Chapman & Hall/CRC Press, 2002
30. Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 73:13-22, 1986
31. Kurland BF, Heagerty PJ: Directly parameterized regression conditioning on being alive: Analysis of longitudinal data truncated by deaths. Biostatistics 6:241-258, 2005 (Pubitemid 41240356)
32. Robins JM, Rotnitzky A, Zhao LP: Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. JASA 90: 106-121, 1995
33. Hogan JW, Laird NM: Mixture models for the joint distribution of repeated measures and event times. Stat Med 16:239-257, 1997 (Pubitemid 27029300)
34. Pauler DK, McCoy S, Moinpour C: Pattern mixture models for longitudinal quality of life studies in advanced stage disease. Stat Med 22:795-809, 2003 (Pubitemid 36266967)
35. Bernhard J, Dietrich D, Scheithauer W, et al: Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: A randomized multicenter phase III clinical trial - SAKK 44/00 - CECOG/PAN. 1.3.001. J Clin Oncol 26:3695-3701, 2008
36. Bramhall SR, Schulz J, Nemunaitis J, et al: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167, 2002
37. Moore MJ, Hamm J, Dancey J, et al: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296-3302, 2003 (Pubitemid 46606263)
38. Van Cutsem E, van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438, 2004 (Pubitemid 41103625)
39. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952, 2006 (Pubitemid 46630743)
40. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007